Eli Lilly Chief Corporate Brand Officer Lina Polimeni on how the brand differentiates itself in the crowded pharma market, ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

Some people are fair-weather friends; others are lifelong. It's a similar story with stocks. Some you might hold only ...

Here, six house and techno artists provide a look into what it’s like being a tastemaker spinning at Time Warp. They discuss their favorite memories, why the event is special to them and more.

The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.

Wall Street investors, spurred on by Trump's pro-business agenda, could be ignoring real risks posed by the president.

The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co. (LLY), Exxon ...